Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.
about
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingThe Tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasisFAM129B/MINERVA, a novel adherens junction-associated protein, suppresses apoptosis in HeLa cellsTWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cellsCRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutationsFOXD3 regulates migration properties and Rnd3 expression in melanoma cellsDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityPathways and therapeutic targets in melanomaBeyond BRAF: where next for melanoma therapy?Current and future trials of targeted therapies in cutaneous melanomaNodal expression and detection in cancer: experience and challengesProtein Depalmitoylation Is Induced by Wnt5a and Promotes Polarized Cell Behavior.Deconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma.Structure-Based Design of an Organoruthenium Phosphatidyl-inositol-3-kinase Inhibitor Reveals a Switch Governing Lipid Kinase Potency and SelectivityStructure of Mediator of RhoA-Dependent Invasion (MRDI) Explains Its Dual Function as a Metabolic Enzyme and a Mediator of Cell InvasionReversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.A ranking method for the concurrent learning of compounds with various activity profiles.Protein-tyrosine kinase 6 promotes peripheral adhesion complex formation and cell migration by phosphorylating p130 CRK-associated substrateDiscovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/DoxCDA: combinatorial drug discovery using transcriptional response modulesWhat does it take to synergistically combine sub-potent natural products into drug-level potent combinations?Perturbation biology: inferring signaling networks in cellular systemsSpatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapyPathway as a pharmacological target for herbal medicines: an investigation from reduning injectionRegistered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivationA melanoma molecular disease modelAcquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3KBRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensionsEvidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity.Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties.Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.Identification of glycogen synthase kinase 3α as a therapeutic target in melanomaTargeted therapy in melanoma.Modeling nasopharyngeal carcinoma in three dimensionsModulation of matrix elasticity with PEG hydrogels to study melanoma drug responsiveness.
P2860
Q21133611-2A6842A7-63EE-4514-8DED-7C24E2B9697EQ24313125-30229890-D2E5-46FA-A1EB-41EB3D4398F2Q24315123-C3F9C1BD-B792-4BD5-BD65-9A846BE1CF8AQ24594566-640D836F-645F-4BF8-93E4-5FE4E98E0A6AQ24618486-B0C600A7-F291-43A2-94D9-EC41FA2CF06FQ24633339-2565B750-9E87-4D88-9934-C65A056FC77AQ24652600-06BFFBEC-210B-4D0A-98B3-A1590DB9B433Q26865736-7C5F9EA0-5AFC-420A-8F40-ECC59768E96AQ27006853-8694C43F-12E6-4AB7-83EB-743BB86E2383Q27022355-DE2566B1-E812-4E77-9980-38218FAF5EF4Q27024576-A5DBA7DD-480F-40D0-B3E6-90A722531363Q27313355-9D03C6DA-C5E5-436E-B723-DE6970C0A109Q27329810-CA9327AB-81AA-41D7-8950-94478951749BQ27650628-C69F92E4-7BAC-411F-ACD2-6195677B3FD1Q27679102-493F44A8-8E13-437E-8791-C42313F0B1E8Q27851698-E62F1DD7-FE24-4E20-AC1E-BC42E52E8504Q27852994-B6254DE8-9462-4AC9-A34D-E3F0BFC277F5Q27853026-E1ADD706-E54C-47E1-AC05-550A43FF336FQ27902271-A2579635-9433-4952-A6A8-583DD093C14AQ28115210-5B689CF9-AD32-4733-B150-101F6865C068Q28477021-BDD52EC1-9475-4D2D-A8E7-BE3A91996E81Q28482122-116D806C-AB51-4AAD-B488-16BF3BD65D1CQ28485360-8E3B60BE-0D8E-434D-B427-0DC8AE0F10AFQ28537769-A46D6D0A-B966-4103-A326-B7D812879E08Q28544732-9E7CAB28-A564-45A9-A418-B5E93EC290B3Q28545279-4DFB4B9E-D534-4943-A66C-100AE3234A68Q28601717-2DC7D19E-AFFE-4496-ADC4-7A2B874556ABQ28741507-E62AD184-777B-464C-A877-C4EA9FAB3D7BQ29614757-86344C28-84DC-4B01-A94C-672A6D730A8DQ30458424-03FC9C03-A2AF-4096-9901-574D7BAD2CE0Q30486572-C6D475A0-27A8-4FBE-A4AB-327A551959B7Q30498197-33D856F5-742E-42F7-B25B-427F419E743BQ30543779-40E8FEB9-7437-47C0-A355-957C119199C9Q30545759-FE3F8A9A-FBF7-45BF-826C-8576CE492B7EQ30746265-A94C74E7-6A69-4B73-BDCD-B0B184471100Q33439312-7FED82C2-B773-4202-97FC-33C8C37962EBQ33569998-3D200D16-074D-46B9-9128-20CE85A1A7A7Q33573107-FE2A236F-12E3-475B-9FB5-2A5B35219197Q33599243-9E60311C-4009-4736-9F10-A83B1220EB2CQ33606461-2FA02F45-A6FE-49A3-B215-E8798C4E2DD6
P2860
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Multiple signaling pathways mu ...... ived from melanoma metastases.
@ast
Multiple signaling pathways mu ...... ived from melanoma metastases.
@en
Multiple signaling pathways mu ...... ived from melanoma metastases.
@nl
type
label
Multiple signaling pathways mu ...... ived from melanoma metastases.
@ast
Multiple signaling pathways mu ...... ived from melanoma metastases.
@en
Multiple signaling pathways mu ...... ived from melanoma metastases.
@nl
prefLabel
Multiple signaling pathways mu ...... ived from melanoma metastases.
@ast
Multiple signaling pathways mu ...... ived from melanoma metastases.
@en
Multiple signaling pathways mu ...... ived from melanoma metastases.
@nl
P2093
P50
P1476
Multiple signaling pathways mu ...... ived from melanoma metastases.
@en
P2093
Mercedes Lioni
Nikolas K Haass
Patricia A Brafford
P304
P356
10.1158/1535-7163.MCT-06-0084
P577
2006-05-01T00:00:00Z